Alligator Bioscience AB (publ) Interim Report January-March 2019
STOCKHOLM, April 17, 2019 /PRNewswire/ -- Significant events January-March
-- First patient dosed in Phase I clinical study of ATOR-1015.
-- New preclinical data presented demonstrating strong anti-tumor effects
for the 4-1BB antibody ATOR-1017.
-- Alligator Bioscience launched RUBY(TM), a novel concept in bispecific
antibody formats.
Events after the end of the period
-- Tumor-localizing properties of ATOR-1015 demonstrated by live imaging.
-- New preclinical data for ATOR-1144 demonstrates potential for activation
of both the innate and the adaptive immune system as well as direct
anti-tumor effects.
Financial information
January-March 2019
-- Net sales, SEK 0.0 million (0.8)
0. Total operating costs SEK -46.7 million (-45.0)
1. Operating result, SEK -46.2 million (-44.0)
2. Earnings per share before and after dilution, SEK -0.62 (-0.59)
3. Cash flow for the period, SEK -34.3 million (0.8)
4. Cash and cash equivalents, including securities, SEK 402.9 million (436.4)
"This is a very exciting year for Alligator. We currently have two projects - ADC-1013 and ATOR-1015 - in clinical development. These projects will soon be joined by ATOR-1017," CEO Per Norlén comments.
Read the complete report in the pdf below.
The information was submitted for publication at 8:00 a.m. CEST on April 17, 2019.
For further information, please contact:
Per Norlén
CEO
per.norlen@alligatorbioscience.com
046-540-82-00
Per-Olof Schrewelius
CFO
per-olof.schrewelius@alligatorbioscience.com
046-540-82-03
Cecilia Hofvander
Director IR & Communications
cecilia.hofvander@alligatorbioscience.com
046-540-82-06
Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden
Phone +46-46-540-82-00
www.alligatorbioscience.com
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit www.alligatorbioscience.com.
ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/12681/2789720/1027439.pdf Alligator Bioscience AB
(publ) Interim report
January-March 2019
View original content:http://www.prnewswire.com/news-releases/alligator-bioscience-ab-publ-interim-report-january-march-2019-300833596.html
SOURCE Alligator Bioscience
